Restax Woman 30cps is a product designed and developed to expand the Restax range.

Restax Woman 30cps is the targeted answer for female alopecia in cases of female estrogen deficiency defluvium, pre-menopausal defluvium, anovulation defluvium.

The clinical picture frequently presenting is as follows:
-Thinning hair
-Thinning hair

Rarely it is also associated:

• Excessive level of androgen hormones with occurrence of hirsutism and acne
• polycystic ovary
• Irregularity of menstrual cycle in childbearing age and anovulation in the pre-menopausal period
• hyperinsulinisation

AGNOCASTO is a natural source of PROGESTERONE which is able to inhibit by naturally regulating 5-alpha-reductase by competition with TESTOSTERONE

AGNOCASTO physiologically reduces the formation of DHT which reduces the activity of ADENYL CYCLASE.

In turn, ADENYL CYCLASIS induces TELOGEN.

AGNOCASTO through P450 AROMATASIS physiologically potentiates the metabolic pathway of ESTRONE (estrogen hormone): increases ADENYLCYCLEASE activity, lengthens ANAGEN phase, and activates STAMINAL cells

In WOMEN the enzyme P450 AROMATASIS is markedly more highly expressed than in humans

The RESVERATROL potent antioxidant and anti-inflammatory, physiologically blocks follicle loss and protects against HYALINOSIS (atrophy/scarring)

La NICOTINAMIDE improves peripheral vasodilatation and follicle perfusion, also increases NADP levels by reducing 5-alpha reductase activity

La BIOTIN must be taken in supplements or through the diet as the body is unable to synthesize it. It is a very important coenzyme for fat and carbohydrate metabolism: its deficiency causes alopecia, thinning and loss of natural hair color.

The PIPER NIGRUM activates intestinal transport carriers and enhances the absorption of active ingredients, making them more BIOAVAILABLE.

In addition, the Piper Nigrum has demonstrated physiological 5-alpha reductase inhibitory activity.

Nutritional values:

Agnocasto e.s. 300mg

Resveratrol 50mg

D-Biotin 450mcg

Piper nigrum 7mg

Vitamin B3 25mg

Posology: 1 capsule during dinner for at least 6 months.

Bibliography
BiolPharm Bull. 2007 Dec;30(12):2402-5; “Testosterone5alpha-reductase inhibitoryactiveconstituents of Piper nigrumleaf”;Hirata N1,Tokunaga M, Naruto S, Iinuma M, Matsuda H. Arnoux M.: “Administration percutanéedesstroïdes” NouvPresMéd1979; 8: 3797; Cherif-Cheik J.L., De Lignieres B.: “Traitement de laséborrhéeducuirchevelu par la progesterone percutanée” Thérapeutique Sem. deshopitaux de Paris 1974; 50: 489. Fayolle J.: “La progesteronepercutanéans le traitement de l’acneet desétatsséborrheiques de la peau et ducuirchevelu. Etude de 66 cas” LyonMedical 1975; 233: 1303. Feldmann R.J., Maibach H.I.: “percutaneous penetration of steroidsin man” J Invest Dermatol 1969; 52: 89. Franceschini P.: “Prévention de la calvitie. Séborrhée etprogestéronepercutanée” Vie Medicale 1975; 1: 1569. Hellman L., Yoshida K., Zumoff B.: “The effect ofmedroxyprogesterone acetate on the pituitary-adrenal axis” J ClinEndocrinMetab1976; 42: 912. Manfredi G.: “Considerations on the antiandrogenic activity ofprogesterone” Med Est 1981; 4: 160. Marliani A.: “The medical therapy of common baldness” EtruriaMedica, Florence, 1992. Mauvais-Jarvis P., Baudod N., Bercovici J.P.: “In vivo studies onprogesterone metabolism by human skin” J ClinEndocrinMetab 1969; 29: 1580. Mauvais-Jarvis P., Kuttenn F., Baudod N.: “Inhibition oftestosterone conversion to dihydrotestosterone in man treated percutaneously byprogesterone” J Clin Endocrinol Metabol 1974; 38: 142. Mauvais-JarvisP.,Kuttenn F., Writh F.: “La progesteroneadministrée per voiepercutanée. Un antiandrogene à actin locale” Annalesd’Endocrinologie 1975; 55: 36. Mauvais-Jarvis P.: “Progésterone et progestatifs” Annalesd’Endocrinologie 1979; 40: 357. Occella C., Schiazza L., Nemelka O., Alpigiani M.G., Rampini E.: “Progesterone in the topical treatment of noninflammatory acne” Med Est1985; 2: 63. Prince V.H.: “Testosterone metabolism in the skin” Arch. Derm1975; 11: 1496. Scheuplein R.J., Blanck I.H., Brauner G.J., MacFarlane D.J.: “Percutaneous absorption of steroids” J Invest Dermatol 1969; 52: 63. Van Der Willigen A.H., Peereboom-Wyna J.D.R., Van Joost Th., StolzE.: “A preliminary study of the effect of 11 alpha-hydroxyprogesterone on thehair growth in men suffering from androgenic alopecia” Acta DermVenereol 1987; 67: 82. Voigt W., Hsia S.L.: “Further studies on testosterone 5 alfareductase of human skin. Structuralfeatures of steroidinhibitors,” J BiolChem1973; 248: 420. Zappalà F., Caruso A., Giardina A., Randazzo S.D.: “Therapeutic activity of progesterone 0.5% solution in some dermatosisandrogen-dependent” Med Est 1983; 3: 113. BiolPharm Bull. 2007 Dec;30(12):2402-5. “Testosterone 5alpha-reductase inhibitoryactive constituents of Piper nigrumleaf. “Hirata N1, Tokunaga M, Naruto S,Iinuma M, Matsuda H.

The technical specifications given are for reference only and subject to change without notice. To obtain more detailed information on product specifications, please contact customer service, via email or telephone contact. Indicative image. Prices and availability updated as of 03/12/2020.